Oral Glibenclamide Suppresses Glucagon Secretion during Insulin-Induced Hypoglycemia in Patients with Type 2 Diabetes1
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Intensifying pharmacological therapy in patients with type 2 diabetes increases the risk of hypoglycemia and often requires the simultaneous use of more than one agent. Combining insulin and sulfonylurea is an effective and frequently used therapy in such patients. However, sulfonylurea derivatives have been shown to affect the release of glucagon, indicating a possible effect of such therapy on hormonal counterregulation to hypoglycemia. Thirteen patients receiving combined therapy were studied on two occasions: 1) after a wash-out period of glibenclamide (−GLIB), and 2) after resuming combined treatment for 6 months (+GLIB). We performed nonstepwise, hyperinsulinemic hypoglycemic clamps using a constant iv insulin infusion and clamping blood glucose at 2.7 mmol/L (48 mg/dL) for 60 min. C Peptide levels were significantly higher during +GLIB, but no significant differences were seen in peripheral plasma insulin levels (+GLIB mean ± sd, 70 ± 17 mU/L vs. −GLIB, 75 ± 14; P = 0.26). Epinephrine responses were similar in the two tests, but when glibenclamide was present the glucagon response was smaller, both the peak value (P = 0.016) and the incremental area under the curve (P = 0.011) as well as the total area under the curve (P = 0.016). These results suggest that intraislet insulin secretion is of importance for the α-cell responsiveness to hypoglycemia in these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Reichard, P., Nilsson, B.-Y., & Rosenqvist, U. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307293290502 · Cited by 1,202 · cited 1×
“A of studies have shown that strict blood glucose control improves the prognosis for patients with type 1 (1, 2) as well as for patients with type 2 diabetes mellitus (3–6).”
BackgroundGroop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“The peripheral insulin levels in our patients (70–75 mU/L) were probably not high enough to completely suppress hepatic glucose production (55), which has to be taken into consideration when interpreting our results.”
BackgroundGerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“diabetes, a few years after onset of the disease (47), appears”
BackgroundIncidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas
Shorr, R. I. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440360095010 · Cited by 459
Schwartz, N. S., Clutter, W. E., Shah, S. D., & Cryer, P. E. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112884 · Cited by 394 · cited 1×
“6 mmol/L, the earliest physiological response in healthy subjects is the suppression of insulin secretion (15).”
BackgroundInsulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“A number of studies have shown that a high insulin level inhibits the release of glucagon both in vitro (21) and in vivo (22–24).”
BackgroundGerich, J. E., Charles, M. A., & Grodsky, G. M. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107823 · Cited by 230 · cited 1×
“Firstly, glucagon may be released through direct stimulation of the a-cells by low glucose (16).”
BackgroundGlucose counterregulation: prevention and correction of hypoglycemia in humans
Cryer, P. E. (1993) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1993.264.2.e149 · Cited by 198 · cited 2×
“Among these hormones, glucagon plays the most important role in the physiological defense against hypoglycemia (7), as implied by the finding that epinephrine cannot fully compensate for an absent glucagon response in normal subjects (8).”
BackgroundInterplay of Nutrients and Hormones in the Regulation of Glucagon Release*
PIPELEERS, D. G., SCHUIT, F. C., SCHRAVENDIJK, C. F. H. V., & WINKEL, M. V. D. (1985) · Endocrinology · doi:10.1210/endo-117-3-817 · Cited by 169 · cited 1×
“However, such a mechanism could not be verified in a study of purified a-cells (17).”
BackgroundCounterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167 · cited 1×
“some (41, 43, 44), whereas others have found that patients”
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Liu, D., Moberg, E., Kollind, M., Lins, P. E., Adamson, U., & Macdonald, I. A. (1992) · Diabetologia · doi:10.1007/bf00400932 · Cited by 162
Self-citationBolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108 · cited 1×
“some (41, 43, 44), whereas others have found that patients”
ResultSUPPRESSION OF COUNTERREGULATORY HORMONE RESPONSE TO HYPOGLYCEMIA BY INSULIN PER SE
DIAMOND, M. P., HALLARMAN, L., STARICK-ZYCH, K., JONES, T. W., CONNOLLY-HOWARD, M., TAMBORLANE, W. V., & SHERWIN, R. S. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-6-1388 · Cited by 107
Effect of Glycemic Control on Glucose Counterregulation During Hypoglycemia in NIDDM
Levy, C. J., Kinsley, B. T., Bajaj, M., & Simonson, D. C. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1330 · Cited by 81
LlU, D., MOBERG, E., KOLLIND, M., LINS, P.-E., & ADAMSON, U. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1123 · Cited by 76
Self-citationEffects of Glycemic Control on Protective Responses Against Hypoglycemia in Type 2 Diabetes
Korzon-Burakowska, A., Hopkins, D., Matyka, K., Lomas, J., Pernet, A., Macdonald, I., & Amiel, S. (1998) · Diabetes Care · doi:10.2337/diacare.21.2.283 · Cited by 71
Bolli, G., De Feo, P., Perriello, G., De Cosmo, S., Compagnucci, P., Santeusanio, F., Brunetti, P., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111315 · Cited by 64
Shamoon, H., Friedman, S., Canton, C., Zacharowicz, L., Hu, M., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117267 · Cited by 57 · cited 1×
“some (41, 43, 44), whereas others have found that patients”
Heller, S. R., Macdonald, I. A., & Tattersall, R. B. (1987) · Diabetologia · doi:10.1007/bf00295875 · Cited by 43
Boden, G., Soriano, M., Hoeldtke, R. D., & Owen, O. E. (1983) · Diabetes · doi:10.2337/diabetes.32.11.1055 · Cited by 43
Research works printed but not linked: 31
- 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group., N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 · DOI · Paper page
- Andersson, 1995, Long-term glycemic control relates to mortality in type II diabetes., Diabetes Care, 18, 1534, 10.2337/diacare.18.12.1534 · DOI · Paper page
- Gaster, 1998, The effects of improved glycemic control on complications in type 2 diabetes., Arch Intern Med, 158, 134, 10.1001/archinte.158.2.134 · DOI · Paper page
- 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group., Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
- De Feo, 1991, Evidence against important catecholamine compensation for absent glucagon counterregulation, Am J Physiol., 260, E203
- Pugh, 1992, Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis., Diabetes Care, 15, 953, 10.2337/diacare.15.8.953 · DOI · Paper page
- Shank, 1995, Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM., Diabetes, 44, 165, 10.2337/diab.44.2.165 · DOI · Paper page
- 1983, The Berson memorial lecture. Insulin-glucagon relationships in the defense against hypoglycemia., Diabetes, 32, 575, 10.2337/diab.32.6.575 · DOI · Paper page
- Hjemdahl, 1979, Determination of plasma catecholamines by high performance liquid chromatography with electrochemical detection: comparison with a radioenzymatic method., Life Sci, 25, 131, 10.1016/0024-3205(79)90384-9 · DOI · Paper page
- Taborsky, 1998, Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired α-cell responses in type 1 diabetes., Diabetes, 47, 995, 10.2337/diabetes.47.7.995 · DOI · Paper page
- Samols, 1983, 2, 133
- Bonner-Weir, 1982, New perspectives on the microvasculature of the islets of Langerhans in the rat., Diabetes, 31, 883, 10.2337/diab.31.10.883 · DOI · Paper page
- Asplin, 1981, In vivo inhibition of glucagon secretion by paracrine beta cell activity in man., J Clin Invest, 68, 314, 10.1172/JCI110251 · DOI · Paper page
- Mellman, 1992, Effect of physiological hyperinsulinemia on counterregulatory hormone responses during hypoglycemia in humans., J Clin Endocrinol Metab, 75, 1293
- Efendic, 1979, Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas., Proc Natl Acad Sci USA, 76, 5901, 10.1073/pnas.76.11.5901 · DOI · Paper page
- Samols, 1969, Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas., Lancet, 1, 174, 10.1016/S0140-6736(69)91189-1 · DOI
- Buchanan, 1969, Pancreatic glucagon release and sulphonylureas., Lancet, 1, 420, 10.1016/S0140-6736(69)91394-4 · doi:10.1016/s0140-6736(69)91394-4
- Kajinuma, 1974, Effects of hypoglycemic sulfonamides on glucagon and insulin secretion in ducks and dogs., Diabetes, 23, 412, 10.2337/diab.23.5.412 · DOI
- Pek, 1972, Failure of sulfonylureas to suppress plasma glucagon in man., Diabetes, 21, 216, 10.2337/diab.21.4.216 · DOI
- Ohneda, 1975, Glucagon response to arginine after treatment of diabetes mellitus., Diabetes, 24, 811, 10.2337/diab.24.9.811 · DOI
- Tsalikian, 1977, The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal., Diabetes, 26, 314, 10.2337/diab.26.4.314 · DOI
- Pfeifer, 1983, Suppression of glucagon secretion during a tolbutamide infusion in normal, and noninsulin-dependent diabetic subjects., J Clin Endocrinol Metab, 56, 586, 10.1210/jcem-56-3-586 · DOI · Paper page
- Lewis, 1994, A new method for comparing portal and peripheral venous insulin delivery in humans: tolbutamide vs. insulin infusion., J Clin Endocrinol Metab, 79, 66
- Peacey, 1997, The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans., J Clin Endocrinol Metab, 82, 1458
- Bohannon, 1982, Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects., J Clin Endocrinol Metab, 54, 459, 10.1210/jcem-54-2-459 · DOI · Paper page
- Polonsky, 1984, Glucose counterregulation in patients after pancreatectomy. Comparison with other clinical forms of diabetes., Diabetes, 33, 1112, 10.2337/diab.33.11.1112 · DOI · Paper page
- Madsbad, 1982, Hormonal, metabolic and cardiovascular responses to hypoglycaemia in type 1 (insulin-dependent) diabetes with and without residual B cell function., Diabetologia, 23, 499, 10.1007/BF00254298 · DOI
- Lev-Ran, 1993, C-Peptide in NIDDM. Follow-up for 4–6 yr., Diabetes Care, 16, 76, 10.2337/diacare.16.1.76 · doi:10.2337/diacare.16.1.76
- Jennings, 1989, Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents., Diabetes Care, 12, 203, 10.2337/diacare.12.3.203 · DOI · Paper page
- Asplund, 1983, Glibenclamide-associated hypoglycaemia: a report on 57 cases., Diabetologia, 24, 412, 10.1007/BF00257338 · DOI · Paper page
- Stepka, 1993, Hypoglycemia: a major problem in the management of diabetes in the elderly., Aging, 5, 117
Cited by
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Hypoglycemia in Type 2 Diabetes
Zammitt, N. N., & Frier, B. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2948 · Cited by 435
Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes
Quesada, I., Tudurí, E., Ripoll, C., & Nadal, Á. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0290 · Cited by 412
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Banarer, S., McGregor, V. P., & Cryer, P. E. (2002) · Diabetes · doi:10.2337/diabetes.51.4.958 · Cited by 194
Metadata
- Authors
- Landstedt-Hallin, L., Adamson, U., & Lins, P.-E.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-09-01
- Volume
- 84
- Issue
- 9
- Pages
- 3140-3145
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2134576974
- Cited by
- 65
- References
- 22
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.